Equity Profile

LEGN

Legend Biotech Corporation

Health CareBiotechnology$5.0B

Dec1Thu

Pre-Earnings Brief

UpcomingQ1-2026After Close5:00 PM EST

Company Snapshot

Legend Biotech Corporation is a biotechnology company focused on developing innovative cell therapies for cancer treatment. As part of the health care sector, its advancements could significantly impact patient outcomes and the overall treatment landscape.

Key Metrics to Watch

Revenue

Revenue growth is crucial for assessing the company's market traction and product acceptance.

N/A

EPS (Earnings Per Share)

EPS indicates the company's profitability and is a key measure for investors.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

In Q1 2024, Legend Biotech reported an EPS of -$0.16, outperforming expectations by 44.44%. However, revenue figures were not disclosed, leaving some uncertainty about overall financial health.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's history of beating EPS estimates. However, the lack of revenue guidance adds a layer of uncertainty.

Bull Case

If Legend Biotech can demonstrate strong revenue growth and continued improvement in EPS, it could signal robust demand for its therapies and lead to a positive market reaction.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about its competitive position and future growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What revenue figures can Legend Biotech provide this quarter?

Revenue clarity is essential for understanding the company's market performance and future growth potential.

Will the company provide guidance on future EPS expectations?

Guidance on EPS will help investors gauge the company's profitability trajectory and overall health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Legend Biotech's therapies to gain traction in the market, especially given recent advancements in cell therapy.

Supporting Evidence

The company has a strong history of beating EPS estimates, which could indicate better-than-expected performance this quarter.

Options pricing suggests a lower expected move compared to historical averages, indicating potential for a larger reaction.

Key Risk

If revenue growth exceeds expectations, it could significantly alter the market's perception of the company's future.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Legend Biotech can sustain growth in a competitive biotech landscape.

Bull Confirmed If

A revenue increase of more than 20% year-over-year would confirm the bull case.

Bear Confirmed If

A revenue decline or stagnant growth would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±5%

Historical Avg

±6.1%

Pricing cheap

The options market is pricing in a 5% move, indicating that investors expect some volatility around the earnings announcement.

Options are pricing ±5.0% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing cheap.

Detail

30d HV

72.4%

Calls (40K)P/C Ratio: 0.32Puts (11K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats expectations and raises guidance, history suggests a positive reaction with an average 1-day move of +1.71%.

In-Line / Cautious

If results are in line but management is cautious, the stock may see muted movement as investors digest the commentary.

Miss

If the company misses expectations, history suggests a potential decline with an average 1-day move of +6.91% in such scenarios.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of ongoing clinical trials.
2Details on partnerships or collaborations that could enhance product development.
3Insights into market demand for their therapies.
4Management's outlook on competitive pressures in the biotech sector.
5Any commentary on regulatory developments affecting their product pipeline.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Elbit Systems Ltd.

Company Snapshot

Key Metrics to Watch

Revenue

Revenue growth is crucial for assessing the company's market traction and product acceptance.

N/A

EPS (Earnings Per Share)

EPS indicates the company's profitability and is a key measure for investors.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

In Q1 2024, Legend Biotech reported an EPS of -$0.16, outperforming expectations by 44.44%. However, revenue figures were not disclosed, leaving some uncertainty about overall financial health.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's history of beating EPS estimates. However, the lack of revenue guidance adds a layer of uncertainty.

Bull Case

If Legend Biotech can demonstrate strong revenue growth and continued improvement in EPS, it could signal robust demand for its therapies and lead to a positive market reaction.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about its competitive position and future growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What revenue figures can Legend Biotech provide this quarter?

Revenue clarity is essential for understanding the company's market performance and future growth potential.

Will the company provide guidance on future EPS expectations?

Guidance on EPS will help investors gauge the company's profitability trajectory and overall health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Legend Biotech's therapies to gain traction in the market, especially given recent advancements in cell therapy.

Supporting Evidence

The company has a strong history of beating EPS estimates, which could indicate better-than-expected performance this quarter.

Options pricing suggests a lower expected move compared to historical averages, indicating potential for a larger reaction.

Key Risk

If revenue growth exceeds expectations, it could significantly alter the market's perception of the company's future.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Legend Biotech can sustain growth in a competitive biotech landscape.

Bull Confirmed If

A revenue increase of more than 20% year-over-year would confirm the bull case.

Bear Confirmed If

A revenue decline or stagnant growth would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±5%

Historical Avg

±6.1%

Pricing cheap

The options market is pricing in a 5% move, indicating that investors expect some volatility around the earnings announcement.

Options are pricing ±5.0% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing cheap.

Detail

30d HV

72.4%

Calls (40K)P/C Ratio: 0.32Puts (11K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats expectations and raises guidance, history suggests a positive reaction with an average 1-day move of +1.71%.

In-Line / Cautious

If results are in line but management is cautious, the stock may see muted movement as investors digest the commentary.

Miss

If the company misses expectations, history suggests a potential decline with an average 1-day move of +6.91% in such scenarios.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of ongoing clinical trials.
2Details on partnerships or collaborations that could enhance product development.
3Insights into market demand for their therapies.
4Management's outlook on competitive pressures in the biotech sector.
5Any commentary on regulatory developments affecting their product pipeline.